{"id":27160,"date":"2024-02-20T17:20:35","date_gmt":"2024-02-20T22:20:35","guid":{"rendered":"https:\/\/myeloma.ca\/?p=27160"},"modified":"2025-08-19T08:28:09","modified_gmt":"2025-08-19T13:28:09","slug":"recipiendaires-2023-de-la-bourse-efcm","status":"publish","type":"post","link":"https:\/\/myeloma.ca\/fr\/2024\/02\/20\/recipiendaires-2023-de-la-bourse-efcm\/","title":{"rendered":"R\u00e9cipiendaires\u202f2023 de la Bourse EFCM\u00a0"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">Au total, 8\u202fbourses EFCM ont \u00e9t\u00e9 <a href=\"https:\/\/myeloma.ca\/wp-content\/uploads\/2024\/01\/Historical-MEET-Grant-Winners_FR.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">attribu\u00e9es en 2023<\/a>. Cliquez sur les liens ci-dessous pour visionner les pr\u00e9sentations vid\u00e9o de certains gagnants et de leur important travail.&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Dory Abelman\u202f: <\/strong><em>Cell-Free DNA from Blood or Bone Marrow as Alternatives to Bone Marrow Cells for Molecular Diagnostics and Monitoring of Multiple Myeloma<\/em> (L\u2019ADN libre de cellules du sang ou de la moelle osseuse comme alternative aux cellules de la moelle osseuse pour le diagnostic mol\u00e9culaire et le suivi d\u2019un my\u00e9lome multiple)&nbsp;<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><em>\u00ab\u2009Je suis profond\u00e9ment reconnaiss<\/em><em>ant<\/em><em> d\u2019avoir re\u00e7u la bourse EFCM du Dr\u202fAndrew R. Belch. Cette bourse <\/em><em>m\u2019a permis<\/em><em> de participer \u00e0 la 65<\/em><em><sup>e<\/sup><\/em><em>\u202fconf\u00e9rence de l\u2019American Society of Hematology. <\/em><em>J\u2019ai pr\u00e9sent\u00e9<\/em><em> aux plus grands h\u00e9matologues d\u2019Am\u00e9rique du Nord notre m\u00e9thode de pointe consistant \u00e0 utiliser des \u00e9chantillons de sang et du mat\u00e9riel de biopsie de moelle osseuse exc\u00e9dentaire pour assurer un suivi pr\u00e9cis du my\u00e9lome multiple. Mon objectif est de r\u00e9duire l\u2019inconfort des patients tout en am\u00e9liorant la pr\u00e9cision du traitement afin de garantir que chacun re\u00e7oive le traitement le plus efficace selon son sous-type de my\u00e9lome\u2009\u00bb.<\/em>&nbsp;<\/li>\n\n\n\n<li><a href=\"https:\/\/youtu.be\/tb24jzeMe30\" target=\"_blank\" rel=\"noopener\" title=\"\">Cliquez ici pour visionner la pr\u00e9sentation<\/a>\u00a0(en anglais seulement)<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>No\u00e9mie Leblay, Ph. D.\u202f:<\/strong> <em>A High-Risk Subgroup Multiple Myeloma Classification Based on the Detection of PR Minor Subclones<\/em> (Classification du my\u00e9lome multiple en sous-groupes \u00e0 haut risque en fonction de la d\u00e9tection de sous-clones mineurs PR)&nbsp;<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><em>\u00ab\u2009La bourse EFCM du Dr\u202fAndrew R. Belch <\/em><em>m\u2019a permis<\/em><em> de participer \u00e0 une <\/em><em>rencontre<\/em><em> internationale consacr\u00e9e aux h\u00e9mopathies malignes. <\/em><em>J\u2019ai eu l<\/em><em>\u2019occasion d\u2019assister \u00e0 des pr\u00e9sentations de pointe sur le my\u00e9lome multiple<\/em><em>. C\u2019\u00e9tait une<\/em><em> excellente occasion de pr\u00e9senter mes recherches, de recevoir une r\u00e9troaction de mes pairs et d\u2019entamer des discussions qui pourraient d\u00e9boucher sur des collaborations.\u2009\u00bb<\/em>&nbsp;<\/li>\n\n\n\n<li><a href=\"https:\/\/youtu.be\/3LX1J3Yuyz8\" target=\"_blank\" rel=\"noopener\" title=\"\">Cliquez ici pour visionner la pr\u00e9sentation<\/a>&nbsp;(en anglais seulement)<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Dre\u202fPallavi Ganguli: <\/strong><em>Primary Care Management Pathways to Reduce Wait Times in Hematology: Monoclonal Gammopathy of Undetermined Significance<\/em> (Protocoles de soins primaires pour r\u00e9duire les temps d\u2019attente en h\u00e9matologie\u202f: gammapathie monoclonale de signification ind\u00e9termin\u00e9e)&nbsp;<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><em>\u00ab\u202fJe suis honor\u00e9e d\u2019avoir re\u00e7u la bourse EFCM du Dr\u202fAndrew R. Belch. Cette bourse soutient les travaux que mes coll\u00e8gues et moi-m\u00eame menons sur la gammapathie monoclonale de signification ind\u00e9termin\u00e9e et les troubles plasmocytaires connexes. Elle contribue ainsi \u00e0 la poursuite des travaux visant \u00e0 am\u00e9liorer le traitement et les r\u00e9sultats des patients atteints de ces maladies.\u202f\u00bb<\/em>&nbsp;<\/li>\n\n\n\n<li><a href=\"https:\/\/youtu.be\/-cX4-eacAMU\" target=\"_blank\" rel=\"noopener\" title=\"\">Cliquez ici pour visionner la pr\u00e9sentation<\/a>\u00a0(en anglais seulement)<\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Au total, 8\u202fbourses EFCM ont \u00e9t\u00e9 attribu\u00e9es en 2023. Cliquez sur les liens ci-dessous pour visionner les pr\u00e9sentations vid\u00e9o de certains gagnants et de leur important travail.&nbsp; Dory Abelman\u202f: Cell-Free DNA from Blood or Bone Marrow as Alternatives to Bone Marrow Cells for Molecular Diagnostics and Monitoring of Multiple Myeloma (L\u2019ADN libre de cellules du [&hellip;]<\/p>\n","protected":false},"author":10,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[53,58,1],"tags":[],"class_list":["post-27160","post","type-post","status-publish","format-standard","hentry","category-actualites-et-evenement","category-nouvelles-de-myelome-canada","category-uncategorized"],"acf":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/27160","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/users\/10"}],"replies":[{"embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/comments?post=27160"}],"version-history":[{"count":2,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/27160\/revisions"}],"predecessor-version":[{"id":27162,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/27160\/revisions\/27162"}],"wp:attachment":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/media?parent=27160"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/categories?post=27160"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/tags?post=27160"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}